| Parameter | Scenario 1 | Scenario 2 |
|---|
| Success rate of first line (LOT1) treatment of DR-TB with bedaquiline | 61% | 80% |
| Peak utilization of bedaquiline-containing regimens in DR-TB treated patients | LOT1 | 85% | 85% |
| LOT2a | 17% | 28% |
| Treatment start date | 2020-Q1 |
| | 2020 | 2021 | 2022 | 2023 | 2024 |
| Adoption of bedaquiline-containing regimens in DR-TB patients (treated with short or long course regimen) | 60% | 70% | 80% | 85% | 85% |
- aPatients failing LOT1 treatment with bedaquiline were assumed to be ineligible for re-treatment with bedaquiline in LOT2, while 85% of patients not treated with bedaquiline in LOT1 were assumed to be treated with bedaquiline in LOT2 in both scenarios
- Abbreviations: LOT line of treatment; DR-TB drug resistant tuberculosis; Q quarter of the year
